Literature DB >> 6300134

Enzymatic toxicogenation of "activated" cyclophosphamide by 3'-5' exonucleases.

L Bielicki, G Voelcker, H J Hohorst.   

Abstract

3'-5' Exonucleases from various sources were found to toxicogenate 4-hydroxycyclophosphamide ("activated" cyclophosphamide) by splitting the oxazaphosphorinane ring and releasing an alkylating moiety and acrolein. Neither cyclophosphamide (CP) nor the deactivated metabolites of CP, 4-keto-CP and carboxyphosphamide nor 4-(S-ethanol)-sulfido-CP were attacked by 3'-5' exonucleases. DNA polymerases with proofreading activity, such as DNA polymerase I from E. coli or DNA polymerase delta from rabbit bone marrow, exhibited a tenfold higher specific activity with "activated" CP than "plain" 3'-5' phosphodiesterases such as snake venom phosphodiesterase or 3',5'cyclic AMP phosphodiesterase from bovine heart tissue. High levels of toxicogenating activity were estimated in peripheric human lymphocytes and tissues of lymphatic origin, suggesting that enzymatic toxicogenation plays a key role with respect to the cytotoxic specificity of "activated" CP.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6300134     DOI: 10.1007/bf00391828

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  12 in total

1.  A new mammalian DNA polymerase with 3' to 5' exonuclease activity: DNA polymerase delta.

Authors:  J J Byrnes; K M Downey; V L Black; A G So
Journal:  Biochemistry       Date:  1976-06-29       Impact factor: 3.162

2.  Enzymatic synthesis of deoxyribonucleic acid. 36. A proofreading function for the 3' leads to 5' exonuclease activity in deoxyribonucleic acid polymerases.

Authors:  D Brutlag; A Kornberg
Journal:  J Biol Chem       Date:  1972-01-10       Impact factor: 5.157

3.  Isolation and identification of 4-ketocyclophosphamide, a possible active form of the antitumor agent cyclophosphamide.

Authors:  D L Hill; M C Kirk; R F Struck
Journal:  J Am Chem Soc       Date:  1970-05-20       Impact factor: 15.419

4.  Fluorometric determination of acrolein and related compounds with m-aminophenol.

Authors:  R A Alarcon
Journal:  Anal Chem       Date:  1968-09       Impact factor: 6.986

5.  Purification of deoxyribonucleic acid polymerase delta from calf thymus: partial characterization of physical properties.

Authors:  M Y Lee; C K Tan; A G So; K M Downey
Journal:  Biochemistry       Date:  1980-05-13       Impact factor: 3.162

6.  Structural and functional properties of calf thymus DNA polymerase delta.

Authors:  M Y Lee; C K Tan; K M Downey; A G So
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  1981

7.  Studies on 4-hydroperoxycyclophosphamide (NSC-181815): a simple preparation method and its application for the synthesis of a new class of "activated" sulfur-containing cyclophosphamide (NSC-26271) derivatives.

Authors:  G Peter; T Wagner; H J Hohorst
Journal:  Cancer Treat Rep       Date:  1976-04

8.  Deactivation of cyclophosphamide (NSC-26271) metabolites by sulfhydryl compounds.

Authors:  J Draeger; G Peter; H J Hohorst
Journal:  Cancer Treat Rep       Date:  1976-04

9.  The problem of oncostatic specificity of cyclophosphamide (NSC-26271): Studies on reactions that control the alkylating and cytotoxic activity.

Authors:  H J Hohorst; U Draeger; G Peter; G Voelcker
Journal:  Cancer Treat Rep       Date:  1976-04

10.  Synthesis and preliminary antitumor evaluation of 4-(SR)-sulfido-cyclophosphamides.

Authors:  G Peter; H J Hohorst
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

View more
  6 in total

1.  Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites.

Authors:  U Schuler; G Ehninger; T Wagner
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat.

Authors:  S Genka; J Deutsch; P L Stahle; U H Shetty; V John; C Robinson; S I Rapoport; N H Greig
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Activated cyclophosphamide: an enzyme-mechanism-based suicide inactivator of DNA polymerase/3'-5' exonuclease.

Authors:  L Bielicki; G Voelcker; H J Hohorst
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

4.  Enhancement of antitumor activity of the oxazaphosphorine cytostatic SUM-IAP by N-methylformamide.

Authors:  G Voelcker
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-03       Impact factor: 4.553

Review 5.  Ifosfamide clinical pharmacokinetics.

Authors:  T Wagner
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

6.  Low toxicity cancer chemotherapy by suicide inactivation of DNA polymerase alpha holoenzyme: first results with new thiazolidinyl- and perhydrothiazinyl-ethyl-N-mustard-phosphamide esters.

Authors:  H J Hohorst; L Bielicki; K Müller; G Voelcker
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.